What's new in June 2011

New for June

• 30 Jun 2011 | Press release: MHRA warns about dangerous ‘herbal’ treatments
  

  Unlicensed herbal remedies for erectile dysfunction, available over the internet, could present serious health risks according to recent test results received by the MHRA.

• 29 Jun 2011 | Medical Device Alert: Implantable cardioverter defibrillator (ICD) manufactured by Sorin CRM (MDA/2011/073)
  

  This Medical Device Alert has been issued because of a risk of bradycardia / syncope due to pacing inhibition. There is also potential for pacing inhibition associated with ventricular oversensing if the follow-up monitoring feature, PhD, is programmed ON and the device is connected to high polarisation defibrillation leads.

• 28 Jun 2011 | Looking for potential drug safety issues in Yellow Card data
  

  

  This page explains how Yellow Cards help in discovering potential drug safety issues.

• 28 Jun 2011 | Public consultation (ARM 76): Request to reclassify Savlon Cold Sore Cream from Pharmacy (P) to General Sale List (GSL)
  

  Consultation ARM 76 seeks your views on the reclassification of Savlon Cold Sore Cream from Pharmacy (P) to General Sale List (GSL).

• 28 Jun 2011 | Impact of the Yellow Card Scheme
  

  This page gives details of safety issues which Yellow Card reports have helped identify.

• 27 Jun 2011 | Weekly list of Field Safety Notices 20 – 24 June 2011
  

  FSNs from medical device manufacturers.

• 27 Jun 2011 | Advice to consumers not to use Africa Black Ant, Rock Hard Weekend, Pandora and The Best, marketed for erectile dysfunction
  

  The MHRA is advising consumers not to use the herbal products specified in this warning due to concerns about possible side effects.

• 24 Jun 2011 | New MHRA Director of Communications
  

  The MHRA this week welcomed its new Director of Communications, Rachel Bosworth.

• 24 Jun 2011 | Rachel Bosworth
  

  Rachel Bosworth took up the post of Director of Communications on 20 June 2011.

• 23 Jun 2011 | Class 3 Drug Alert (Action within 5 days): Ebewe Pharma Ges.m.b.H.Nfg.KG - Fludarabine phosphate 25mg/ml - EL (11)A/18
  

  Ebewe Pharma Ges.m.b.H.Nfg.KG is recalling all remaining stock of three batches of Fludarabine phosphate 25mg/ml as a precautionary measure because routine testing has shown that a known impurity is present at higher levels than expected.